You are subscribed to the FormularyWatch.

Formulary

eNewsletter Subscribe

July 3, 2014

Web Version  | Share with a colleague

Facebook Like Twitter Tweet

Today's Headlines

FDA approves rapid-acting, inhaled insulin for diabetes

FDA approved insulin human Inhalation Powder (Afrezza, MannKind), a rapid-acting inhaled insulin to improve glycemic control in adults with diabetes mellitus. » Full article

Support consumer access to specialty drugs through value-based insurance design

The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value, according to researchers. » Full article

Continuing Education

MTM essentials for heart failure management

This month's article is the fifth in a year-long CPE series, Medication Therapy Management Considerations for Adult Patients with Cardiovascular Disease. From February 2014 through January 2015, pharmacists can earn up to 24 hours of CPE credit with 12 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.

The goal of this month's activity is to review the stages and pharmacologic strategies relevant to medication therapy management of heart failure.

To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to log in.


Announcement: Welcome to the new user registration process. This new process requires all pharmacists and pharmacy technicians to provide or update their NABP e-Profile ID in order to electronically keep track of CPE credits from ACPE-accredited providers. If you have not done so, you can obtain your NABP e-Profile ID now at www.MyCPEmonitor.net. This profile will enable you to have one login for all the NABP programs and services you will need throughout your career.

 

Related Articles

Drugs in Context: Farxiga (dapagliflozin)

Specialty drug pricing pushing envelope for hospital pharmacies

RESOURCES

Latest Clinical News

EDITOR'S PICK

EULAR: Sarilumab investigational anti-IL-6R therapy shows positive results in rheumatoid arthritis treatment

Positive results were presented from a phase 3 trial of investigational drug sarilumab in rheumatoid arthritis (RA) patients who were inadequate responders to methotrexate (MTX) therapy, at the European League Against Rheumatism Annual Congress (EULAR 2014) Congress in Paris, France. » Full article

Powered by Modern Medicine Advanstar Medical Communications Group